Fig. 5
From: An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs
Extension of the dosing interval promoted LVRNA001 effectiveness in mice. Mice were immunized with different doses of LVRNA001 (2.5 μg or 0.625 μg) or PBS. A second dose of LVRNA001 was administered at 3 days (0d/3d), 7 days (0d/7d), and 14 days (0d/14d) after first immunization. (A–B) Mouse serum samples were collected at 14, 28 and 84 dpi, and neutralizing antibody levels were measured by FAVN tests. n = 6/group. *, p < 0.05. **, p < 0.01. ***, p < 0.001. C Mice were intracerebrally challenged with 50-fold LD50 of the virulent RABV-CVS-24 strain, the survival rates at 14 days post-challenge were calculated. n = 10/group